TY  - CONF

T1  - Cost-Effectiveness of LDL-C Lowering With Evolocumab In Patients With High Cardiovascular Risk In The United States

JO  - Value in Health

PY  - 2016/05/01

AU  - Gandra SR

AU  - Villa G

AU  - Fonarow G

AU  - Lothgren M

AU  - Lindgren P

AU  - Somaratne R

AU  - van Hout B

ED  - 

DO  - DOI: 10.1016/j.jval.2016.03.029

PB  - Elsevier BV

VL  - 19

IS  - 3

SP  - A3

EP  - A3

Y2  - 2024/10/22

ER  -